Who is sponsoring NCT02994251?

NCT02994251 is sponsored by Yale University.

What drugs are being tested in NCT02994251?

Interventions in NCT02994251: gemcitabine, Cisplatin, Conventional TACE (transarterial chemoembolization) with Doxorubicin/Mitomycin-C.

What condition does NCT02994251 study?

NCT02994251 studies Unresectable Intrahepatic Cholangiocarcinoma.

Is NCT02994251 still recruiting?

NCT02994251 is currently terminated. Last updated 30 December 2019.

Are results published for NCT02994251?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2019-12-30 · How we verify

NCT02994251

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Trial of Systemic Chemotherapy in Combination With Conventional Transarterial Chemoembolization in Patients With Advanced Intra-Hepatic Cholangiocarcinoma

Terminated Phase 2 Results posted Last updated 30 December 2019

What this trial tests

Phase 2 trial testing gemcitabine in Unresectable Intrahepatic Cholangiocarcinoma in 1 participant. Terminated before completion.

Timeline

21 June 2017

Primary endpoint
6 November 2018

6 November 2018

Quick facts

Lead sponsor	Yale University
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	1
Start date	21 June 2017
Primary completion	6 November 2018
Estimated completion	6 November 2018
Sites	1 location across United States

Drugs / interventions tested

gemcitabine (gemcitabine) — full drug profile →
Cisplatin (cisplatin) — full drug profile →
Conventional TACE (transarterial chemoembolization) with Doxorubicin/Mitomycin-C — full drug profile →

Conditions studied

Unresectable Intrahepatic Cholangiocarcinoma — all drugs for Unresectable Intrahepatic Cholangiocarcinoma →

Sponsor

Yale University

Who can join

18 and older, any sex, with Unresectable Intrahepatic Cholangiocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study will be a single-center, single-arm, Phase II study of gemcitabine and cisplatin in combination with conventional trans-arterial chemoembolization therapy in adult patients with advanced ICC. 25 patients will be enrolled over the course of 2 years, with an additional 1.5 years for patient follow-up.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Lipiodol Deposition and Washout in Primary and Metastatic Liver Tumors After Chemoembolization.
Nezami N, VAN Breugel JMM, Konstantinidis M, Chapiro J, et al · · 2021 · cited 13× · PMID 34697157 · DOI 10.21873/invivo.12621

Verify or expand the search:

Other trials of gemcitabine

Trials testing the same drug.

NCT06694454 — Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immun · Phase 1, PHASE2 · not yet recruiting
NCT07353294 — Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC · Phase 1 · not yet recruiting
NCT06897644 — Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherap · Phase 3 · recruiting
NCT05562297 — Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer · Phase 2 · not yet recruiting
NCT06388720 — The Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential Therapy · Phase 2 · recruiting

Other recruiting trials for Unresectable Intrahepatic Cholangiocarcinoma

Currently open trials in the same condition.

NCT06058663 — Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Ch · Phase 1 · recruiting
NCT05564403 — Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH T · Phase 2 · active not recruiting
NCT04251715 — mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectab · Phase 2 · active not recruiting
NCT04175912 — Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver · Phase 2 · active not recruiting
NCT03942328 — Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition Af · Phase 1, PHASE2 · recruiting

Other Yale University trials

Trials by the same sponsor.

NCT06900998 — Pilot Study: Effects of Nimodipine on Alcohol Drinking · Phase 2 · not yet recruiting
NCT04910984 — Developing a Chatbot to Promote HIV Testing · NA · not yet recruiting
NCT07458087 — Accuracy of the Accuro 3S · NA · not yet recruiting
NCT07398404 — A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Pa · Phase 1, PHASE2 · not yet recruiting
NCT07305324 — Improving Liver Fibrosis Diagnosis in Primary Care Using FibroX AI · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02994251 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yale University
Last refreshed: 30 December 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02994251.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing